Chinese expert consensus on diagnosis and treatment of radiation pneumonitis
暂无分享,去创建一个
[1] Yi-long Wu,et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. , 2022, The Lancet. Oncology.
[2] Jeong Yun Jang,et al. Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study , 2021, Radiation Oncology.
[3] Keunchil Park,et al. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer , 2021, JAMA oncology.
[4] Jinming Yu,et al. Computed tomography-based delta-radiomics analysis for discriminating radiation pneumonitis in patients with esophageal cancer after radiation therapy. , 2021, International journal of radiation oncology, biology, physics.
[5] E. Hau,et al. A systematic review and meta-analysis of treatment-related toxicities of curative and palliative radiation therapy in non-small cell lung cancer , 2021, Scientific Reports.
[6] Hongyu Wu,et al. Risk factors for radiation pneumonitis in lung cancer patients with subclinical interstitial lung disease after thoracic radiation therapy , 2021, Radiation oncology.
[7] D. Lynch,et al. Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. , 2021, Radiology.
[8] D. Lynch,et al. Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. , 2021, Chest.
[9] O. Arrieta,et al. Radiation-induced lung injury: current evidence , 2021, BMC Pulmonary Medicine.
[10] U. Dafni,et al. Progression-free and overall survival for concurrent nivolumab with standard concurrent chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: Results from the European Thoracic Oncology Platform NICOLAS phase II trial (ETOP 6-14). , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[11] Jinming Yu,et al. Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications , 2020, BMC Medicine.
[12] Q. Lin,et al. Stereotactic body radiotherapy for early stage non-small cell lung cancer in patients with subclinical interstitial lung disease , 2020, Translational lung cancer research.
[13] A. Sheshadri,et al. Immune-Related Adverse Events: Pneumonitis , 2020, Advances in experimental medicine and biology.
[14] Ying Zhou,et al. Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters , 2019, Strahlentherapie und Onkologie.
[15] Hsuan-Fu Kuo,et al. Azithromycin suppresses Th1- and Th2-related chemokines IP-10/MDC in human monocytic cell line. , 2019, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.
[16] V. Jendrossek,et al. The CD73/Ado System—A New Player in RT Induced Adverse Late Effects , 2019, Cancers.
[17] J. Cadranel,et al. Dramatic Radiation Recall Pneumonitis Induced by Osimertinib after Palliative Thoracic Radiotherapy for Lung Cancer. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[18] E. Weiss,et al. Fatal Radiation Pneumonitis: Literature Review and Case Series , 2019, Advances in radiation oncology.
[19] Jun Liang,et al. Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy , 2019, BMC Cancer.
[20] S. Kroeze,et al. Combination of stereotactic radiotherapy and targeted therapy: patterns-of-care survey in German-speaking countries , 2019, Strahlentherapie und Onkologie.
[21] C. Lin,et al. Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[22] R. Sullivan,et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis , 2018, JAMA oncology.
[23] Geoffrey D. Hugo,et al. Diabetes mellitus and radiation induced lung injury after thoracic stereotactic body radiotherapy. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[24] Jinming Yu,et al. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors , 2018, Journal of Hematology & Oncology.
[25] R. Mohan,et al. Clinical and Dosimetric Factors Predicting Grade ≥2 Radiation Pneumonitis After Postoperative Radiotherapy for Patients With Non-Small Cell Lung Carcinoma. , 2018, International journal of radiation oncology, biology, physics.
[26] Tinsu Pan,et al. Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study , 2018, Quality of Life Research.
[27] Tarek Mekhail,et al. Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[28] Wei Chen,et al. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] N. Viñolas,et al. Feasibility, tolerability, and efficacy of the concurrent addition of erlotinib to thoracic radiotherapy in locally advanced unresectable non-small-cell lung cancer: a Phase II trial , 2016, OncoTargets and therapy.
[30] W. Mao,et al. Analysis of Clinical and Dosimetric Factors Influencing Radiation-Induced Lung Injury in Patients with Lung Cancer , 2015, Journal of Cancer.
[31] Shulian Wang,et al. Nondosimetric risk factors for radiation-induced lung toxicity. , 2015, Seminars in radiation oncology.
[32] Yang Yao,et al. Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials , 2015, Journal of chemotherapy.
[33] Randall K Ten Haken,et al. Effect of normal lung definition on lung dosimetry and lung toxicity prediction in radiation therapy treatment planning. , 2013, International journal of radiation oncology, biology, physics.
[34] Jun Liang,et al. Management and outcome of symptomatic radiation induced lung injury in non-small cell lung cancer , 2013 .
[35] Jae-Sung Kim,et al. Predictors of radiation pneumonitis and pulmonary function changes after concurrent chemoradiotherapy of non-small cell lung cancer , 2013, Radiation oncology journal.
[36] Tae Hyun Kim,et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. , 2013, International journal of radiation oncology, biology, physics.
[37] I. Vogelius,et al. A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis , 2012, Acta oncologica.
[38] E. Gore,et al. Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy. , 2012, International journal of radiation oncology, biology, physics.
[39] Lujun Zhao,et al. Risk factors for radiation-induced lung toxicity in patients with non-small cell lung cancer who received postoperative radiation therapy. , 2012, Lung cancer.
[40] Joseph O. Deasy,et al. Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Based Hybrid Patient and Physician Questionnaire for Head and Neck (HN) Radiotherapy Symptom Reporting , 2011 .
[41] Myungsoo Kim,et al. Factors predicting radiation pneumonitis in locally advanced non-small cell lung cancer , 2011, Radiation oncology journal.
[42] Hubert Thierens,et al. Predicting risk of radiation-induced lung injury. , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[43] R. Komaki,et al. Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: a meta-analysis. , 2007, International journal of radiation oncology, biology, physics.
[44] Randall K Ten Haken,et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. , 2006, International journal of radiation oncology, biology, physics.
[45] A. Sasse,et al. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. , 2006, International journal of radiation oncology, biology, physics.
[46] Jeffrey Bradley,et al. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. , 2005, International journal of radiation oncology, biology, physics.
[47] Joos V Lebesque,et al. Regional differences in lung radiosensitivity after radiotherapy for non-small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.
[48] David Pérol,et al. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[49] T. Samulski,et al. ASSESSMENT OF THE PROTECTIVE EFFECT OF AMIFOSTINE ON RADIATION-INDUCED PULMONARY TOXICITY , 2002, Experimental lung research.
[50] T. Raffin,et al. Pulmonary radiation injury. , 1997, Chest.
[51] D. Gandara,et al. Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] A. Arden,et al. Development of radiation pneumonitis. Time and dose factors. , 1962, Archives of pathology.
[53] V. Kouloulias,et al. Suggestion for a new grading scale for radiation induced pneumonitis based on radiological findings of computerized tomography: correlation with clinical and radiotherapeutic parameters in lung cancer patients. , 2013, Asian Pacific journal of cancer prevention : APJCP.
[54] B. Ozturk,et al. Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial. , 2004, International journal of radiation oncology, biology, physics.
[55] S. Johnson. Guidelines for patients. , 1991, Journal of obstetric, gynecologic, and neonatal nursing : JOGNN.
[56] H. Libshitz,et al. Complications of radiation therapy: the thorax. , 1974, Seminars in roentgenology.